Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target $26.15 +5.10 (+24.23%) (As of 11/27/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Arrowhead Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 10 Analyst RatingsSell0Hold3Buy7 Based on 10 Wall Street analysts who have issued ratings for Arrowhead Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 3 have given a hold rating, and 7 have given a buy rating for ARWR. Consensus Price Target $42.5662.74% Upside According to the 10 analysts' twelve-month price targets for Arrowhead Pharmaceuticals, the average price target is $42.56. The highest price target for ARWR is $60.00, while the lowest price target for ARWR is $26.00. The average price target represents a forecasted upside of 62.74% from the current price of $26.15. Get the Latest News and Ratings for ARWR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up ARWR Analyst Ratings Over TimeTypeCurrent Forecast11/30/23 to 11/29/241 Month Ago10/31/23 to 10/30/243 Months Ago9/1/23 to 8/31/241 Year Ago11/30/22 to 11/30/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy7 Buy rating(s)7 Buy rating(s)6 Buy rating(s)10 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)5 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$42.56$45.33$44.25$54.00Forecasted Upside62.74% Upside130.00% Upside85.69% Upside154.72% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. ARWR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ARWR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Arrowhead Pharmaceuticals Stock vs. The CompetitionTypeArrowhead PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.70 2.80 2.50Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside62.74% Upside24,757.92% Upside6.55% UpsideNews Sentiment RatingNeutral NewsSee Recent ARWR NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/27/2024Piper Sandler2 of 5 stars Lower TargetOverweight ➝ Overweight$62.00 ➝ $45.00+90.52%11/27/2024Citigroup3 of 5 stars Lower TargetNeutral ➝ Neutral$27.00 ➝ $26.00+7.08%11/27/2024Chardan Capital1 of 5 stars Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+185.04%11/20/2024HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+224.50%9/26/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00+110.00%9/9/2024Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweightBill Gates’ is about to mint millionaires (again) with Stargate. (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know.8/12/2024B. RileySubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00+139.65%6/5/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageNeutral$31.00+22.58%5/13/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetEqual Weight ➝ Equal Weight$36.00 ➝ $27.00+23.74%1/2/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$29.00 ➝ $37.00+17.61%7/21/2023TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform5/12/2023Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingM. ForooharSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/12/2023SVB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOutperform ➝ Market Perform$40.00-0.20%5/3/2023500.comSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingReiterates4/26/2023Sumitomo Mitsui Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$80.00+138.24%3/21/2023Sanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageMarket Perform$27.00+7.74%2/7/2023Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform$60.00 ➝ $58.00+73.08%11/29/2022Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy$92.00 ➝ $75.00+150.00%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:38 AM ET. ARWR Forecast - Frequently Asked Questions What is Arrowhead Pharmaceuticals' forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Arrowhead Pharmaceuticals is $42.56, with a high forecast of $60.00 and a low forecast of $26.00. Should I buy or sell Arrowhead Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARWR shares. Does Arrowhead Pharmaceuticals's stock price have much upside? According to analysts, Arrowhead Pharmaceuticals's stock has a predicted upside of 62.74% based on their 12-month stock forecasts. What analysts cover Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Chardan Capital, Citigroup, HC Wainwright, Piper Sandler, and Royal Bank of Canada in the past 90 days. Do Wall Street analysts like Arrowhead Pharmaceuticals more than its competitors? Analysts like Arrowhead Pharmaceuticals less than other "medical" companies. The consensus rating score for Arrowhead Pharmaceuticals is 2.70 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ARWR compares to other companies. Stock Forecasts and Research Tools Related Companies RVMD Stock Forecast ROIV Stock Forecast ITCI Stock Forecast ASND Stock Forecast LEGN Stock Forecast NUVL Stock Forecast ELAN Stock Forecast LNTH Stock Forecast BPMC Stock Forecast CYTK Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. This page (NASDAQ:ARWR) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts